Prostacyclin signalling through prostacyclin receptor

Stable Identifier
R-HSA-392851
Type
Pathway
Species
Homo sapiens
Compartment
ReviewStatus
5/5
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser
Prostacyclin (PGI2) is continuously produced by healthy vascular endothelial cells. It inhibits platelet activation through interaction with the Gs-coupled receptor PTGIR, leading to increased cAMP, a consequent increase in cAMP-dependent protein kinase activity which prevents increases of cytoplasmic [Ca2+] necessary for activation (Woulfe et al. 2001). PGI2 is also an effective vasodilator. These effects oppose the effects of thromboxane (TXA2), another eicosanoid, creating a balance of blood circulation and platelet activation.
Literature References
PubMed ID Title Journal Year
17164137 Human prostacyclin receptor structure and function from naturally-occurring and synthetic mutations

Douville, KL, Stitham, J, Arehart, EJ, Hwa, J, Gleim, SR

Prostaglandins Other Lipid Mediat 2007
Participants
Participates
Orthologous Events
Cross References
BioModels Database
Authored
Reviewed
Created
Cite Us!